Ovid Therapeutics Inc (OVID) Stock Analysis
Verdict: WATCH (do not buy)
Clinical pipeline potential is offset by severe cash burn ($38.3M/yr) and reliance on binary Phase 2 trial outcomes.
Investment score: 50/100
Analysis as of
Is Ovid Therapeutics Inc stock worth reviewing? AI model thesis
The AI model rates Ovid Therapeutics (OVID) as a HOLD. While analysts project significant upside to $5.50 based on pipeline candidates like OV329 and OV350, fundamental financial burn and valuation multiples demand caution.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Ovid Therapeutics Inc opportunities and risks
What speaks for OVID
- Multiple neurological pipeline candidates with clinical readouts expected through 2027–2029.
What speaks against OVID
- High cash burn rate relative to liquid cash balance.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| OVID | n/a | 337.8x | n/a | 96.8% | -2178.9% | -10.2% |
| MDXG | 108.3x | 1.8x | 21.0x | 78.8% | 1.8% | 6.4% |
| MPLT | n/a | 0.0x | n/a | 0.0% | 0.0% | -35.8% |
| ALT | n/a | 19792.4x | n/a | -48306.5% | -296000.0% | -12.5% |
| RGNX | n/a | 2.6x | n/a | 54.2% | -112.6% | -54.8% |
| ARTV | n/a | 0.0x | n/a | 0.0% | 0.0% | -17.0% |
| Peer median | n/a | 1.8x | n/a | 0.0% | 0.0% | -17.0% |
Frequently asked questions about Ovid Therapeutics Inc (OVID)
Is OVID stock a good investment?
The cached TradeMates AI model rates Ovid Therapeutics Inc as WATCH (do not buy) with an investment score of 50/100. The AI model rates Ovid Therapeutics (OVID) as a HOLD. While analysts project significant upside to $5.50 based on pipeline candidates like OV329 and OV350, fundamental financial burn and valuation multiples demand caution. This is algorithmic model output, not personal investment advice.
Is OVID stock a buy?
The TradeMates model verdict for OVID is WATCH (do not buy) with an investment score of 50/100. Treat this as a model signal to review, not a personal buy recommendation.